Smith & Nephew (SN) Stock Price, Fundamentals & Analysis

What SN does

Smith & Nephew (SN) is a Healthcare company in the Medical Devices industry, listed on the London Stock Exchange and headquartered in Watford, United Kingdom. With around 17,000 employees, it develops, manufactures, markets, and sells medical devices and services across the United Kingdom, the United States, and internationally. The business is organised into three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Its product range includes knee and hip implants, trauma and extremities devices for fracture stabilisation and deformity correction, and sports medicine instruments and implants for minimally invasive joint repair.

Smith & Nephew is part of the FTSE 100. Investors seeking broader exposure to UK-listed healthcare names often compare it with peers such as AstraZeneca (AZN) and GSK plc (GSK), or with diversified consumer-health companies like Haleon (HLN).

Key numbers explained

• Price is currently 10.08 GBP, sitting near the lower end of its 9.91 – 14.27 52-week range. The stock is down 24.1% over the past year.
• The trailing P/E ratio of 18 shows what investors pay per unit of recent earnings; the forward P/E ratio of 11.1 reflects expected earnings, suggesting analysts anticipate growth.
• The dividend yield of 2.91% indicates roughly 2.9% of the share price is returned annually to shareholders. Smith & Nephew pays out 52% of earnings as dividends, with the next ex-dividend date on Oct 1, 2026.
• Beta of 0.68 means the share historically moves less than the overall market.
• Revenue of 6.3B USD grew 4.6% year over year, with a profit margin of 10.1% and operating margin of 14.5%.
• Return on equity of 11.9% measures how effectively the company generates profit from shareholders' capital.
• The debt-to-equity ratio of 73.1% indicates a moderate level of leverage.

What to watch

• Earnings reports: the next earnings date is Aug 4, 2026. Results will be scrutinised for revenue growth and margin trends.
• Segment performance: orthopaedics and sports medicine demand, along with wound management trends, drive the overall picture.
• Regulatory and reimbursement shifts in key markets can affect device sales and hospital spending.
• Currency moves, as the company reports in USD while trading in GBP.
• Capital allocation decisions, including dividend policy and reinvestment across its three segments.

Analysts following the medical-device space may also reference companies like Convatec (CTEC) or Fresenius Medical Care (FME) for comparison. For a full list of UK-listed names, see London Stock Exchange stocks.